



SMAR.P-001
Patent Application

131
include which, if any, of the levels of the indicators in the patient sample differ significantly from levels of the same indicators in normal mammals of the same species.

Please amend claims 6 and 7 to read as follows:

B2 6. (amended) The method according to claim 4, wherein the step of determining the levels of at least three indicators comprises performing immunoassays to detect the indicators.

7. (amended) The method of claim 4, further comprising the step of determining an additional indicator, said additional indicator being the level of pepsinogen I multiplied by the level of Helicobacter pylori antibodies, wherein the level of this additional indicator is compared to a value in the standard matrix.

REMARKS

This is in response to the Official Action mailed March 23, 2001 for the above-captioned application. Reconsideration of the application in view of the remarks herein is respectfully requested.

Applicants request an extension of time sufficient to make this response timely, and enclose the appropriate fee. The Commissioner is authorized to charge any additional fees or credit any overpayment to Deposit Account No. 15-0610.

Applicants apologize for the inadvertent inclusion of the '594 Patent on the Substitute for PTO 1449.

Applicants will address the draftsman's concerns with the drawings upon receipt of an indication of allowance.

The Examiner rejected claim 7 under 35 USC § 112, as being an improper dependent claim, asserting that it broadens the scope of claim 4. Claim 7 has been amended to more clearly address this rejection.

The Examiner rejected claims 1-8 under 35 USC § 102 as anticipated by Lindgren